| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Werewolf Therapeutics (NASDAQ:HOWL) through any online brokerage.
Other companies in Werewolf Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Werewolf Therapeutics has a consensus price target of $6.50.
The stock price for Werewolf Therapeutics (NASDAQ: HOWL) is $0.91 last updated October 2, 2026 at 7:59 PM EDT.
There are no upcoming dividends for Werewolf Therapeutics.
Werewolf Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Werewolf Therapeutics.
Werewolf Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
